Trial Profile

Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucidinostat (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors Chipscreen Biosciences

04 Jun 2024 Interim Results (at data cut off January 10, 2023)presented at the 60th Annual Meeting of the American Society of Clinical Oncology
30 Apr 2024 According to Chipscreen Biosciences media release,The results of the interim analysis of the DEB Phase III study were selected as the Late breaking Abstract (LBA) for the American Society of Clinical Oncology (ASCO) Annual Meeting on April 24, 2024.
30 Apr 2024 Results published in the Chipscreen Biosciences Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com